25
Participants
Start Date
December 7, 2021
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2040
T cells or CAR T cells
"There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur."
Pembrolizumab Injectable Product
2 mg/kg/dose (max 200 mg/dose) every 3 weeks
Nivolumab Injectable Product
3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
RECRUITING
Texas Children's Hospital, Houston
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
The Faris Foundation USA
UNKNOWN
Stand Up To Cancer
OTHER
Triumph Over Kid Cancer Foundation
UNKNOWN
St. Baldrick's Foundation
OTHER
National Cancer Institute (NCI)
NIH
Baylor College of Medicine
OTHER